Yang Haojun, Zhu Jie, Wang Guangyao, Liu Hanyang, Zhou Yan, Qian Jun
Department of Gastrointestinal Center, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Front Cell Dev Biol. 2020 Oct 8;8:582695. doi: 10.3389/fcell.2020.582695. eCollection 2020.
The development of colorectal cancer (CRC) is often sporadic, but its etiology is multifactorial. Chemoresistance of CRC leads to tumor recurrence and poor prognosis in patients. The phosphorylation of protein kinase B (AKT) can activate metabolic reprogramming toward cellular glycolysis. Serine/threonine kinase 35 (STK35) regulates the cell cycle and is frequently associated with cancer progression, whereas little is known about its specific roles in CRC. In the current study, bioinformatics analyses were performed to investigate the relationship between STK35 and CRC prognosis. STK35 knockdown and overexpressing CRC cells were established to examine its functions in CRC. Fluorouracil (5-FU) was utilized to evaluate the effect of STK35 on CRC chemoresistance. Moreover, co-immunoprecipitation was performed to explore the ubiquitination of STK35. STK35 was highly expressed in CRC, and its protein expression was negatively correlated with the survival of CRC patients. Furthermore, STK35 overexpression could promote glycolysis, suppress apoptosis, upregulate p-AKT, and counteract the antitumor functions of 5-FU and neural precursor cell expressed developmentally downregulated gene 4-like (NEDD4L) in CRC cells. NEDD4L was associated with and could ubiquitinate STK35. STK35 could be a prognostic biomarker for CRC prognosis and has promotive effects on CRC cellular activities, partially through the AKT pathway. Moreover, STK35 also interferes with the chemosensitivity of CRC.
结直肠癌(CRC)的发生通常是散发性的,但其病因是多因素的。CRC的化疗耐药导致肿瘤复发和患者预后不良。蛋白激酶B(AKT)的磷酸化可激活细胞向糖酵解的代谢重编程。丝氨酸/苏氨酸激酶35(STK35)调节细胞周期,且常与癌症进展相关,而其在CRC中的具体作用尚不清楚。在本研究中,进行了生物信息学分析以研究STK35与CRC预后之间的关系。构建了STK35敲低和过表达的CRC细胞系,以研究其在CRC中的功能。使用氟尿嘧啶(5-FU)评估STK35对CRC化疗耐药性的影响。此外,进行了免疫共沉淀以探究STK35的泛素化情况。STK35在CRC中高表达,其蛋白表达与CRC患者的生存率呈负相关。此外,STK35过表达可促进糖酵解、抑制细胞凋亡、上调p-AKT,并抵消5-FU和神经前体细胞表达的发育下调基因4样蛋白(NEDD4L)在CRC细胞中的抗肿瘤功能。NEDD4L与STK35相关且可使STK35泛素化。STK35可能是CRC预后的一个预后生物标志物,并且对CRC细胞活性具有促进作用,部分是通过AKT途径。此外,STK35还会干扰CRC的化疗敏感性。